

Zolgensma Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

The Business Research Company's Zolgensma Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 14, 2025

[/EINPresswire.com/](https://www.einpresswire.com/) -- Updated 2025

Market Reports Released: Trends,

Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



How Has the [Zolgensma Market](#) Grown Historically, and What Does the Future Hold?

- The Zolgensma market has experienced a compound annual growth rate (CAGR) of XX% in recent years, driven by factors such as growing awareness of genetic disorders, increased healthcare expenditure, and the rising adoption of genetic testing. The market is projected to expand from \$XX million in 2024 to \$XX million in 2025.
- Looking ahead, the market is forecasted to grow at an XX% future CAGR (FCAGR), reaching \$XX million by 2029. Contributing factors include the growing focus on personalized medicine, rising healthcare investments, expansion of telemedicine, advancements in digital health



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!"

The Business research company

technologies, and an increasing emphasis on treating rare diseases.

Get Your Free Sample Market Report

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20373&type=smp>

What Factors Are Driving the Zolgensma Market Growth?

The rising prevalence of Spinal Muscular Atrophy (SMA) is a major driver of the Zolgensma market. SMA, a condition characterized by motor neuron degeneration in the spinal cord, leads to progressive muscle weakness, particularly in infants and young children. Advances in genetic

testing and newborn screening programs have significantly improved early and precise diagnosis, fueling market growth.

Zolgensma directly addresses the genetic cause of SMA by delivering a functional copy of the SMN1 gene, restoring survival motor neuron (SMN) protein production essential for muscle function. This therapy has demonstrated significant improvements in motor skills and survival rates among affected infants and children. For example, as of November 2022, 118 out of 161 SMA Type 1 patients were over two years old and living without permanent ventilatory support. Such outcomes highlight the increasing need for effective SMA treatment, further driving Zolgensma market expansion.

Order Your Report Now for Swift Delivery

<https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report>

Which Key Players Are Leading the Zolgensma Market?

Novartis AG is a dominant force in the Zolgensma market, leveraging advancements in gene therapy technologies and implementing strategic initiatives to expand its market presence.

What Are the Latest Trends in the Zolgensma Market?

A significant trend shaping the Zolgensma market is the emphasis on strategic investments to enhance production capacity, expand geographical reach, and accelerate research and development for innovative gene therapies. For instance, in April 2022, Novartis AG secured commercial licensure from the U.S. Food and Drug Administration (FDA) for its multi-product gene therapy manufacturing facility in Durham, North Carolina. This approval underscores the industry's commitment to advancing gene therapy solutions.

How Is the [Zolgensma Market Segmented](#)?

The Zolgensma market is categorized based on the following segments:

1. By Indication: Spinal Muscular Atrophy (SMA) Type 1, SMA Type 2, SMA Type 3, Pre-symptomatic SMA
2. By Age Group: Pediatric (Infants and Children), Adults
3. By Distribution Channel: Hospitals, Specialty Clinics, Pharmacies

Which Regions Dominate the Zolgensma Market?

North America held the largest share of the Zolgensma market in 2024. However, significant market presence is also observed across regions such as Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Cell and Gene Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report>

Gene Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report>

Cell & Gene Therapy Manufacturing Services Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report>

[Learn More About The Business Research Company](#)

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/793466077>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.